Phenotypic heterogeneity in severe hemophilia

被引:101
作者
Van den Berg, H. M.
De Groot, P. H. G.
Fischer, K.
机构
[1] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Van Creveldklin, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Internal Med, Van Creveldklin, NL-3508 GA Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, NL-3508 GA Utrecht, Netherlands
关键词
clinical phenotype; coagulation; severe haemophilia; thrombin generation;
D O I
10.1111/j.1538-7836.2007.02503.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Large heterogeneity in bleeding pattern and arthropathy is observed among patients with severe hemophilia. Studies have reported a large variability in bleeding pattern among patients with severe hemophilia. Of special interest are some 10% of the patients with severe hemophilia who only rarely bleed and don't need prophylactic therapy. Prothrombotic risk factors seem to influence phenotype but they can account for only a small part of the heterogeneity. Half-lives for factor VIII (FVIII) range between 7 and 20 h; a significantly shorter half-life has been reported in patients with blood group O and a low von Willebrand antigen level. In addition, thrombin generation tests have been used to differentiate between mild and more severe phenotypes. As the advanced forms of these tests also measure the effects of platelets, it has been argued that they are more sensitive to differentiate phenotypes. We conclude that the origin of the large heterogeneity of phenotypes in severe hemophilia is multifactorial. As they produce no FVIII, patients with severe hemophilia and an intron 22 inversion are ideal candidates to study further bleeding variability. Until other parameters have been identified, the heterogeneity of the clinical phenotype may best be predicted by the first onset of the clinical features. At the moment, age at first joint bleed seems to be the most reliable factor to differentiate between phenotypes.
引用
收藏
页码:151 / 156
页数:6
相关论文
共 40 条
[1]   A LONGITUDINAL-STUDY OF ORTHOPEDIC OUTCOMES FOR SEVERE FACTOR-VIII-DEFICIENT HEMOPHILIACS [J].
ALEDORT, LM ;
HASCHMEYER, RH ;
PETTERSSON, H ;
EIBL, H ;
GILBERT, M ;
HILGARTNER, M ;
KUNSHACK, M ;
LARRIEU, MJ ;
LEVINE, P .
JOURNAL OF INTERNAL MEDICINE, 1994, 236 (04) :391-399
[2]   Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A [J].
Bassus, S. ;
Wegert, W. ;
Krause, M. ;
Escuriola-Ettinghausen, C. ;
Siegemund, A. ;
Petros, S. ;
Scholz, T. ;
Scharrer, I. ;
Kreuz, W. ;
Engelmann, L. ;
Kirchmaier, C. M. .
PLATELETS, 2006, 17 (06) :378-384
[3]   Haemophilias A and B [J].
Bolton-Maggs, PHB ;
Pasi, KJ .
LANCET, 2003, 361 (9371) :1801-1809
[4]   Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma? [J].
Bos, MHA ;
Meijerman, DWE ;
Van der Zwaan, C ;
Mertens, K .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (03) :522-530
[5]   Models of blood coagulation [J].
Butenas, S ;
van't Veer, C ;
Cawthern, K ;
Brummel, KE ;
Mann, KG .
BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 :S9-S13
[6]   Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B [J].
Dargaud, Y ;
Béguin, S ;
Lienhart, A ;
Al Dieri, R ;
Trzeciak, C ;
Bordet, JC ;
Hemker, HC ;
Negrier, C .
THROMBOSIS AND HAEMOSTASIS, 2005, 93 (03) :475-480
[7]  
ESCURIOLAETTING.C, 2001, THROMB HAEMOSTASIS, V85, P215
[8]   INTERINDIVIDUAL VARIATION IN HALF-LIFE OF INFUSED RECOMBINANT FACTOR-VIII IS RELATED TO PRE-INFUSION VON-WILLEBRAND-FACTOR ANTIGEN LEVELS [J].
FIJNVANDRAAT, K ;
PETERS, M ;
TENCATE, JW .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (02) :474-476
[9]  
Fischer K, 2000, THROMB HAEMOSTASIS, V84, P977
[10]   FACTOR-VIII GENE REARRANGEMENTS IN PATIENTS WITH SEVERE HEMOPHILIA-A [J].
GOODEVE, AC ;
PRESTON, FE ;
PEAKE, IR .
LANCET, 1994, 343 (8893) :329-330